Dr Reddys Company Profile
What is the competitive landscape for DR REDDYS
DR REDDYS has three hundred and seventy-three approved drugs.
There are three US patents protecting DR REDDYS drugs. There are nineteen tentative approvals on DR REDDYS drugs.
Summary for Dr Reddys
| US Patents: | 3 |
| Tradenames: | 302 |
| Ingredients: | 273 |
| NDAs: | 373 |
Drugs and US Patents for Dr Reddys
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dr Reddys | TESTOSTERONE | testosterone | INJECTABLE;INJECTION | 086417-001 | Jul 7, 1983 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Dr Reddys | CEFAZOLIN SODIUM | cefazolin sodium | INJECTABLE;INJECTION | 062988-003 | Dec 29, 1989 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Dr Reddys | TREPROSTINIL | treprostinil | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 210214-004 | May 22, 2020 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Dr Reddys Labs Sa | NICOTINE POLACRILEX | nicotine polacrilex | TROCHE/LOZENGE;ORAL | 213233-001 | Aug 4, 2020 | OTC | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Dr Reddys | EPHEDRINE SULFATE | ephedrine sulfate | SOLUTION;INTRAVENOUS | 212649-001 | Oct 3, 2020 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Dr Reddys | ESZOPICLONE | eszopiclone | TABLET;ORAL | 091024-003 | Apr 15, 2014 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Dr Reddys | RIVAROXABAN | rivaroxaban | TABLET;ORAL | 208534-003 | May 14, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Dr Reddys
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Dr Reddys Labs Sa | HABITROL | nicotine | FILM, EXTENDED RELEASE;TRANSDERMAL | 020076-006 | Nov 12, 1999 | 4,597,961 | ⤷ Start Trial |
| Dr Reddys Labs Sa | HABITROL | nicotine | FILM, EXTENDED RELEASE;TRANSDERMAL | 020076-004 | Nov 12, 1999 | 4,597,961 | ⤷ Start Trial |
| Dr Reddys Labs Sa | HABITROL | nicotine | FILM, EXTENDED RELEASE;TRANSDERMAL | 020076-005 | Nov 12, 1999 | 4,597,961 | ⤷ Start Trial |
| Dr Reddys Labs Sa | TRI-NORINYL 21-DAY | ethinyl estradiol; norethindrone | TABLET;ORAL-21 | 018977-001 | Apr 13, 1984 | 4,390,531 | ⤷ Start Trial |
| Dr Reddys Labs Sa | HABITROL | nicotine | FILM, EXTENDED RELEASE;TRANSDERMAL | 020076-005 | Nov 12, 1999 | 5,834,011 | ⤷ Start Trial |
| Dr Reddys Labs Sa | HABITROL | nicotine | FILM, EXTENDED RELEASE;TRANSDERMAL | 020076-004 | Nov 12, 1999 | 5,834,011 | ⤷ Start Trial |
| Dr Reddys Labs Sa | HABITROL | nicotine | FILM, EXTENDED RELEASE;TRANSDERMAL | 020076-006 | Nov 12, 1999 | 5,016,652 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for DR REDDYS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
International Patents for Dr Reddys Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2016132270 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2022172253 | ⤷ Start Trial |
| Argentina | 124867 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Dr Reddys Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1255752 | CA 2008 00015 | Denmark | ⤷ Start Trial | PRODUCT NAME: SUNITINIB EVT. I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, HERUNDER L-MALEATSALTET |
| 0245997 | 2000C/005 | Belgium | ⤷ Start Trial | PRODUCT NAME: DOFETILIDE; REGISTRATION NO/DATE: EU/1/99/121/001 19991129 |
| 1261606 | 08C0051 | France | ⤷ Start Trial | PRODUCT NAME: RIVAROXABAN; REGISTRATION NO/DATE: EU/1/08/472/001-008 20080930 |
| 2515855 | CR 2018 00002 | Denmark | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF GLYCOPYRRONIUM BROMIDE, FORMOTEROL OR A SALT THEREOF, INCLUDING FORMOTEROL FUMARATE DIHYDRATE, AND BECLOMETASONE DIPROPIONATE; REG. NO/DATE: EU/1/17/1208 20170719 |
| 1830843 | CR 2015 00036 | Denmark | ⤷ Start Trial | PRODUCT NAME: NINTEDANIB ELLER EN TAUTOMER, BLANDINGERNE DERAF ELLER ET SALT DERAF, SAERLIGT NINTEDANIB ESILAT; REG. NO/DATE: EU/1/14/979/001-004 20150119 |
| 1532149 | 92128 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3, 7-DIHYDROPURIN-2, 6-DION, LES ENANTIOMERES ET LEURS SELS, EN PARTICULIER LA LINAGLIPTINE COMBINEE AVEC DU CHLORHYDRATE DE METFORMINE. LINAGLIPTINE |
| 2207786 | 23C1052 | France | ⤷ Start Trial | PRODUCT NAME: UNE COMPOSITION COMPRENANT: LA CEDAZURIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, ET LA DECITABINE; REGISTRATION NO/DATE: EU/1/23/1756 20230918 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
